Enliven Research Development from 2010 to 2025

ELVN Stock   22.47  0.28  1.23%   
Enliven Therapeutics Research Development yearly trend continues to be very stable with very little volatility. Research Development is likely to grow to about 78 M this year. During the period from 2010 to 2025, Enliven Therapeutics Research Development quarterly data regression pattern had sample variance of 648 T and median of  8,239,000. View All Fundamentals
 
Research Development  
First Reported
2019-03-31
Previous Quarter
18.8 M
Current Value
21.3 M
Quarterly Volatility
5.9 M
 
Covid
Check Enliven Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enliven Therapeutics' main balance sheet or income statement drivers, such as Other Operating Expenses of 100.9 M, Research Development of 78 M or Total Operating Expenses of 100.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.89. Enliven financial statements analysis is a perfect complement when working with Enliven Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Enliven Therapeutics Correlation against competitors.
To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.

Latest Enliven Therapeutics' Research Development Growth Pattern

Below is the plot of the Research Development of Enliven Therapeutics over the last few years. It is Enliven Therapeutics' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enliven Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

Enliven Research Development Regression Statistics

Arithmetic Mean22,945,950
Geometric Mean14,696,273
Coefficient Of Variation110.94
Mean Deviation19,505,675
Median8,239,000
Standard Deviation25,456,015
Sample Variance648T
Range70.1M
R-Value0.79
Mean Square Error262.4T
R-Squared0.62
Significance0.0003
Slope4,216,944
Total Sum of Squares9720.1T

Enliven Research Development History

202578 M
202474.3 M
202364.6 M
202231 M
202120.5 M
20208.2 M
201919 M

About Enliven Therapeutics Financial Statements

Enliven Therapeutics investors utilize fundamental indicators, such as Research Development, to predict how Enliven Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Research Development74.3 M78 M
When determining whether Enliven Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enliven Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enliven Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enliven Therapeutics Stock:
Check out the analysis of Enliven Therapeutics Correlation against competitors.
To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.89)
Return On Assets
(0.21)
Return On Equity
(0.31)
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.